Icariin synergistically inhibits glycolysis and mitochondrial energy metabolism in lung cancer in association with the HIF-1α/LONP1 axis.
AIM OF THE STUDY Non-small cell lung cancer (NSCLC) accounts for the vast majority of lung cancer cases and remains a therapeutic challenge due to drug resistance, adverse effects, and metabolic plasticity. Icariin (ICR), a principal bioactive flavonoid from Epimedium, exhibits promising antitumor properties; however,...